Orgenesis Inc (ORGS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Orgenesis Inc (ORGS) has a cash flow conversion efficiency ratio of 0.193x as of September 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.63 Million) by net assets ($-23.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Orgenesis Inc (ORGS) net asset quality to measure how much of total assets are equity-financed.
Orgenesis Inc - Cash Flow Conversion Efficiency Trend (2009–2023)
This chart illustrates how Orgenesis Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ORGS cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Orgenesis Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Orgenesis Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SKY E&M Co. Ltd
KQ:131100
|
0.027x |
|
Opus One Resources Inc
V:OOR
|
-0.055x |
|
Acceleware Ltd
V:AXE
|
0.030x |
|
Middle Island Resources Ltd
AU:MDI
|
-0.200x |
|
Hammer Metals Limited
F:6HM
|
-0.006x |
|
Akora Resources Ltd
AU:AKO
|
-0.058x |
|
Medicure Inc
V:MPH
|
-0.144x |
|
Edinburgh Worldwide Investment Trust plc
LSE:EWI
|
-0.013x |
Annual Cash Flow Conversion Efficiency for Orgenesis Inc (2009–2023)
The table below shows the annual cash flow conversion efficiency of Orgenesis Inc from 2009 to 2023. For the full company profile with market capitalisation and key ratios, see Orgenesis Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $-20.98 Million | $-14.84 Million | 0.707x | +268.16% |
| 2022-12-31 | $59.27 Million | $-24.92 Million | -0.420x | +39.54% |
| 2021-12-31 | $38.63 Million | $-26.87 Million | -0.695x | +53.02% |
| 2020-12-31 | $52.73 Million | $-78.05 Million | -1.480x | +31.95% |
| 2019-12-31 | $6.08 Million | $-13.22 Million | -2.175x | -382.15% |
| 2018-12-31 | $28.65 Million | $-12.92 Million | -0.451x | +17.59% |
| 2018-11-30 | $28.65 Million | $-15.68 Million | -0.547x | -101.69% |
| 2017-12-31 | $14.12 Million | $-3.83 Million | -0.271x | +24.11% |
| 2016-12-31 | $10.58 Million | $-3.78 Million | -0.358x | -185.11% |
| 2015-12-31 | $-6.44 Million | $-2.71 Million | 0.420x | -12.41% |
| 2014-12-31 | $-2.98 Million | $-1.43 Million | 0.480x | -50.94% |
| 2013-12-31 | $-2.03 Million | $-1.99 Million | 0.978x | -73.91% |
| 2012-12-31 | $-280.56K | $-1.05 Million | 3.748x | +163859.98% |
| 2011-12-31 | $-82.67K | $-189.00 | 0.002x | -99.84% |
| 2010-12-31 | $-10.32K | $-14.96K | 1.449x | +258.94% |
| 2009-12-31 | $25.85K | $-23.58K | -0.912x | -- |
About Orgenesis Inc
Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of res… Read more